Keyphrases
Atrial Fibrillation
100%
Anticoagulant Activity
100%
Bleeding Outcomes
100%
Dabigatran Etexilate
100%
Hemoclot Thrombin Inhibitor Assay
60%
Bleeding Events
50%
Prothrombin Time
20%
Activated Partial Thromboplastin Time (aPTT)
20%
Independent Risk Factors
10%
Time Measurement
10%
Receiver Operating Characteristic Curve
10%
Renal Function
10%
High Variability
10%
90th Percentile
10%
Male Sex
10%
Blood Samples
10%
Bleeding
10%
Bleeding Rate
10%
Kaplan-Meier Analysis
10%
Multiple Time Points
10%
Special Circumstances
10%
Prospective Follow-up
10%
Anticoagulant Effect
10%
HAS-BLED
10%
Multivariate Cox Regression Analysis
10%
C-statistic
10%
Non-valvular Atrial Fibrillation
10%
Stroke History
10%
Routine Care
10%
Coagulation Tests
10%
Nursing and Health Professions
Atrial Fibrillation
100%
Anticoagulation
100%
Dabigatran Etexilate
100%
Thrombin Inhibitor
60%
Bleeding
20%
Activated Partial Thromboplastin Time
20%
Prothrombin Time
20%
Kaplan Meier Method
10%
Proportional Hazards Model
10%
Anticoagulant Agent
10%
Blood Sampling
10%
Blood Clotting Test
10%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Anticoagulant Activity
100%
Dabigatran Etexilate
100%
Thrombin Inhibitor
60%
Bleeding
20%
Prothrombin
20%
Thromboplastin
20%
Anticoagulant Agent
10%